A majority of people with advanced cancers endure cachexia, a muscle-, fat-, and organ-wasting condition that is currently ...

MUNICH--(BUSINESS WIRE)--CatalYm today announced new findings from its ongoing Phase 1/2a study as well as preclinical research, highlighting the therapeutic potential of its lead drug candidate, ...

Cancer ravages both body and mind. If you've ever lost loved ones to the disease, you might recognize the physical and emotional changes cancer patients often endure during their final months. They ...

Ponsegromab increased weight and activity levels in cachexia patients, confirming GDF-15 as a key driver and therapeutic target. Significant weight gain was observed in ponsegromab-treated groups ...

Case involving senior dosimetrist at a premier cancer hospital in the Northeast suggests potential relevance of Phyto-N in one of oncology’s most ...

Please provide your email address to receive an email when new articles are posted on . Patients with cancer cachexia assigned ponsegromab gained significantly more weight than those assigned placebo.

Curanex Pharmaceuticals Inc. CURX on Monday said that a recent patient case study may reinforce its strategic push into ...

Study met primary endpoint of change from baseline in body weight for ponsegromab compared to placebo across all ponsegromab doses tested, reaching 5.6% mean increase at the highest dose evaluated at ...

Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia (ku-KEK-see-uh), a common condition related to cancer that involves weight loss and ...

When new data for anamorelin were presented at a large European meeting in 2014, oncology experts enthusiastically welcomed them, and hopes were raised that there may at last be a drug for cancer ...

Preclinical and clinical data demonstrate that neutralizing GDF-15 with visugromab effectively alleviates cancer-induced cachexia, characterized by severe weight and muscle mass loss Patients with ...